WO2004080483A1 - Targeted agents for both photodiagnosis and photodynamic therapy - Google Patents

Targeted agents for both photodiagnosis and photodynamic therapy Download PDF

Info

Publication number
WO2004080483A1
WO2004080483A1 PCT/US2004/007525 US2004007525W WO2004080483A1 WO 2004080483 A1 WO2004080483 A1 WO 2004080483A1 US 2004007525 W US2004007525 W US 2004007525W WO 2004080483 A1 WO2004080483 A1 WO 2004080483A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
agents
imaging
moiety
pdt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/007525
Other languages
English (en)
French (fr)
Inventor
Charles W. Spangler
Aleksander Rebane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MPA Technologies Inc
Original Assignee
MPA Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MPA Technologies Inc filed Critical MPA Technologies Inc
Priority to JP2006507106A priority Critical patent/JP2006522102A/ja
Priority to AU2004220530A priority patent/AU2004220530A1/en
Priority to CA002523605A priority patent/CA2523605A1/en
Priority to EP04719315A priority patent/EP1613351A1/en
Publication of WO2004080483A1 publication Critical patent/WO2004080483A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention further provides methods of detecting and/or treating disease, most notably cancer, by the activation of the PDT moiety using light at the appropriate wavelength to activate the moiety.
  • the methods can also be combined with other imaging modalities.
  • Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp. Cell Res. 251 , 67-78 (1999); Hao, J.L. et al. Effect of galardin on collagen degradation by Pseudomonas aeruginosa. Exp. Eye Res. 69, 595-601 (1999); Hao, J.L. et al. Galardin inhibits collagen degradation by rabbit keratocytes by inhibiting the activation of pro-matrix metalloproteinases. Exp. Eye Res. 68, 565-572 (1999); Wallace, G.R. et al.
  • Seprase has been implicated in breast cancer and is involved in an early event in the progression from a non-invasive premalignant phenotype to the invasive malignant phenotype. It is a 170 kDa dimer, and is a serine integral membrane protease (with a putative standard catalytic triad) with gelanitinase activity. The monomer 97 kDa form is inactive. The catalytic domain is exposed to the extracellular environment. Seprase is overexpressed in neoplasic invasive ductal carcinoma (IDC) cells and exhibits low levels of expression in benign proliferative tissue or normal breast cells. It also may activate MMPs. It degrades gelatin and collagen. See Kelly et al, Mod. Path. 11(9):855 (1998), incorporated by reference.
  • IDC neoplasic invasive ductal carcinoma
  • the targeting moiety is a lipid.
  • “Lipid” as used herein includes fats, fatty oils, waxes, phospholipids, glycolipids, terpenes, fatty acids, and glycerides, particularly the triglycerides. Also included within the definition of lipids are the eicosanoids, steroids and sterols, some of which are also hormones, such as prostaglandins, opiates, and cholesterol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2004/007525 2003-03-10 2004-03-10 Targeted agents for both photodiagnosis and photodynamic therapy Ceased WO2004080483A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006507106A JP2006522102A (ja) 2003-03-10 2004-03-10 光診断法および光線力学的療法の両方のためのターゲット剤
AU2004220530A AU2004220530A1 (en) 2003-03-10 2004-03-10 Targeted agents for both photodiagnosis and photodynamic therapy
CA002523605A CA2523605A1 (en) 2003-03-10 2004-03-10 Targeted agents for both photodiagnosis and photodynamic therapy
EP04719315A EP1613351A1 (en) 2003-03-10 2004-03-10 Targeted agents for both photodiagnosis and photodynamic therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45361803P 2003-03-10 2003-03-10
US60/453,618 2003-03-10

Publications (1)

Publication Number Publication Date
WO2004080483A1 true WO2004080483A1 (en) 2004-09-23

Family

ID=32990795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007525 Ceased WO2004080483A1 (en) 2003-03-10 2004-03-10 Targeted agents for both photodiagnosis and photodynamic therapy

Country Status (6)

Country Link
US (1) US20040247527A1 (https=)
EP (1) EP1613351A1 (https=)
JP (1) JP2006522102A (https=)
AU (1) AU2004220530A1 (https=)
CA (1) CA2523605A1 (https=)
WO (1) WO2004080483A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104271A3 (en) * 2007-02-28 2008-11-06 Sanofi Aventis Imaging probes
US7780875B2 (en) 2005-01-13 2010-08-24 Cinvention Ag Composite materials containing carbon nanoparticles
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354433B2 (en) * 2003-02-28 2008-04-08 Advanced Light Technologies, Llc Disinfection, destruction of neoplastic growth, and sterilization by differential absorption of electromagnetic energy
US20110040295A1 (en) * 2003-02-28 2011-02-17 Photometics, Inc. Cancer treatment using selective photo-apoptosis
US20080268013A1 (en) * 2005-02-10 2008-10-30 Emory University Polyethylene Oxide Polymers Including Anti-Inflammatory Glycodendrons
US20080070802A1 (en) * 2006-08-23 2008-03-20 Moerschell Richard P Directed heterobifunctional linkers
WO2008030624A2 (en) * 2006-09-08 2008-03-13 The Research Foundation Of State University Of New York Nanoparticles for two-photon activated photodynamic therapy and imaging
US20080233051A1 (en) * 2006-09-08 2008-09-25 Prasad Paras N Nanoparticles for two-photon activated photodynamic therapy and imaging
US20090069673A1 (en) * 2007-03-16 2009-03-12 The Charles Stark Draper Laboratory, Inc. Spinal needle optical sensor
US9226917B2 (en) * 2008-12-16 2016-01-05 Valeant Pharmaceuticals International, Inc. Photodynamic therapy for conditions of the eye
WO2011037622A1 (en) * 2009-09-22 2011-03-31 Photometics Cancer treatment using selective photo-apoptosis
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
US8883503B2 (en) 2011-06-23 2014-11-11 Indian Institute Of Technology Kanpur Hydrogel scaffolds for tissue engineering
CA2953371C (en) 2014-06-30 2021-08-24 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
JP7057278B2 (ja) * 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052746A1 (en) * 2000-01-18 2001-07-26 Mallinckrodt Inc. Versatile hydrophilic dyes
US20020156117A1 (en) * 2000-01-18 2002-10-24 Mallinckrodt Inc. Receptor-avid exogenous optical contrast and therapeutic agents
WO2003004466A2 (en) * 2001-07-03 2003-01-16 Mallinckrodt Inc. Dye-sulfenates for dual phototherapy
WO2003003806A2 (en) * 2001-07-03 2003-01-16 Mallinckrodt, Inc. Dye-azide compounds for dual phototherapy
WO2003011106A2 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
WO2003032901A2 (en) * 2001-10-17 2003-04-24 Mallinckrodt Inc. Pathological tissue detection and treatment employing targeted benzoindole optical agents
WO2003032900A2 (en) * 2001-10-17 2003-04-24 Mallinckrodt Inc. Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
WO2003032902A2 (en) * 2001-10-17 2003-04-24 Mallinckrodt Inc. Tumor targeted photodiagnostic-phototherapeutic agents
WO2003065888A1 (en) * 2002-02-07 2003-08-14 Mallinckrodt Inc. Dye-bioconjugates for simultaneous optical diagnostic and therapeutic applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US5832931A (en) * 1996-10-30 1998-11-10 Photogen, Inc. Method for improved selectivity in photo-activation and detection of molecular diagnostic agents
US6217848B1 (en) * 1999-05-20 2001-04-17 Mallinckrodt Inc. Cyanine and indocyanine dye bioconjugates for biomedical applications
EP1424942B1 (en) * 2001-08-22 2008-12-31 Montana State University-Bozeman Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052746A1 (en) * 2000-01-18 2001-07-26 Mallinckrodt Inc. Versatile hydrophilic dyes
US20020156117A1 (en) * 2000-01-18 2002-10-24 Mallinckrodt Inc. Receptor-avid exogenous optical contrast and therapeutic agents
US20030036538A1 (en) * 2000-01-18 2003-02-20 Mallinckrodt Inc. Dye-sulfenates for dual phototherapy
WO2003004466A2 (en) * 2001-07-03 2003-01-16 Mallinckrodt Inc. Dye-sulfenates for dual phototherapy
WO2003003806A2 (en) * 2001-07-03 2003-01-16 Mallinckrodt, Inc. Dye-azide compounds for dual phototherapy
WO2003011106A2 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
WO2003032901A2 (en) * 2001-10-17 2003-04-24 Mallinckrodt Inc. Pathological tissue detection and treatment employing targeted benzoindole optical agents
WO2003032900A2 (en) * 2001-10-17 2003-04-24 Mallinckrodt Inc. Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
WO2003032902A2 (en) * 2001-10-17 2003-04-24 Mallinckrodt Inc. Tumor targeted photodiagnostic-phototherapeutic agents
WO2003065888A1 (en) * 2002-02-07 2003-08-14 Mallinckrodt Inc. Dye-bioconjugates for simultaneous optical diagnostic and therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACHILEFU S ET AL: "NOVEL RECEPTOR-TARGETED FLUORESCENT CONTRAST AGENTS FOR IN VIVO TUMOR IMAGING", INVESTIGATIVE RADIOLOGY, PHILADELPHIA, PA, US, vol. 35, no. 8, 2000, pages 479 - 485, XP000978923 *
BECKER A ET AL: "RECEPTOR-TARGETED OPTICAL IMAGING OF TUMORS WITH NEAR-INFRARED FLUORESCENT LIGANDS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 19, April 2001 (2001-04-01), pages 327 - 331, XP001168699, ISSN: 1087-0156 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780875B2 (en) 2005-01-13 2010-08-24 Cinvention Ag Composite materials containing carbon nanoparticles
WO2008104271A3 (en) * 2007-02-28 2008-11-06 Sanofi Aventis Imaging probes
US8771644B2 (en) 2007-02-28 2014-07-08 Sanofi Imaging probes
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9448164B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9448165B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for control of illumination or radiation collection for blood glucose and other analyte detection and measurement using collision computing
US9453794B2 (en) 2014-09-29 2016-09-27 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9459202B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for collision computing for detection and noninvasive measurement of blood glucose and other substances and events
US9459203B2 (en) 2014-09-29 2016-10-04 Zyomed, Corp. Systems and methods for generating and using projector curve sets for universal calibration for noninvasive blood glucose and other measurements
US9610018B2 (en) 2014-09-29 2017-04-04 Zyomed Corp. Systems and methods for measurement of heart rate and other heart-related characteristics from photoplethysmographic (PPG) signals using collision computing
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing

Also Published As

Publication number Publication date
CA2523605A1 (en) 2004-09-23
JP2006522102A (ja) 2006-09-28
AU2004220530A1 (en) 2004-09-23
US20040247527A1 (en) 2004-12-09
EP1613351A1 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
US20040247527A1 (en) Multifunctional photodynamic agents for treating of disease
Fujita et al. Activity-based fluorescence diagnostics for cancer
Akers et al. Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe
Sano et al. Short PEG-linkers improve the performance of targeted, activatable monoclonal antibody-indocyanine green optical imaging probes
US9968691B2 (en) PSMA-targeted NIR dyes and their uses
Hu et al. Recent advances in indocyanine green-based probes for second near-infrared fluorescence imaging and therapy
EP2114462B1 (en) Compounds for fluorescence imaging
US7473415B2 (en) Near infrared fluorescent contrast agent and method for fluorescence imaging
US20040234454A1 (en) Pathological tissue detection and treatment employing targeted benzoindole optical agents
US20110177007A1 (en) Dithienopyrrole Dyes for Imaging and Therapy
CN101687040A (zh) 整合光活性的小分子及其用途
US20110264026A1 (en) Azo Derivatives and Uses Thereof in Phototherapy
JP2011051900A (ja) 組込み型光活性ペプチドおよびその使用
US20030105299A1 (en) Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
JP2003535041A (ja) 広用途の親水性染料
Hentzen et al. Molecular fluorescence‐guided surgery of peritoneal carcinomatosis of colorectal origin: A narrative review
US20110196231A1 (en) Fused Ring Thiophene Dyes for Imaging and Therapy
JP2006503798A (ja) 同時光学診断および治療適用のための染料バイオコンジュゲート
US20250009908A1 (en) Fluorescently Labeled Immunoglobulin Single Variable Domains
US8731655B2 (en) Compounds containing acyclic N-N bonds for phototherapy
US20030105300A1 (en) Tumor targeted photodiagnostic-phototherapeutic agents
US20110288033A1 (en) Disulfide Compounds for Phototherapy
US9186349B2 (en) Diaza heterocyclic compounds for phototherapy
Allémann et al. Pharmaceutical technology at the service of targeted drug delivery
van der Plas Bsc Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: A narrative review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006507106

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004220530

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004719315

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2523605

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004220530

Country of ref document: AU

Date of ref document: 20040310

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004220530

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004719315

Country of ref document: EP